Fintel reports that on January 3, 2025, Guggenheim upgraded their outlook for Surrozen (NasdaqCM:SRZN) from Neutral to Buy.

Guggenheim analyst Yatin Suneja upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Don't Miss Our New Year's Offers:Discover ...

As previously reported, Guggenheim upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Recent Phase 1b data for SZN-043, the ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted ...

Shares of SRZN opened at $14.25 on Friday. Surrozen has a fifty-two week low of $6.00 and a fifty-two week high of $16.19. The firm has a 50-day simple moving average of $10.78 and a 200-day ...

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

As of 13:53:07 GMT-5. Market open. SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted ...